AMH and myeloid sarcoma: A study of women of reproductive age (N = 134) reported lower mean AMH levels in patients with MS (2.47 ± 0.26 ng/ml) compared with healthy controls (3.34 ± 0.34 ng/ml; p < 0.04) (21); in contrast, a larger study (N = 592) with a broader age range (22–65 years) found no difference in AMH levels by MS status (0.98-fold difference [95% CI, 0.69–1.37]; p = 0.87) (22).